Evotec SE (EVO)
USD 4.33
(-9.41%)
USD 4.33
(-9.41%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 626.19 Million EUR | 23.59% |
| 2022 | 506.67 Million EUR | -1.22% |
| 2021 | 512.91 Million EUR | 4.26% |
| 2020 | 491.96 Million EUR | 6.23% |
| 2019 | 463.09 Million EUR | 304.58% |
| 2018 | 114.46 Million EUR | -39.73% |
| 2017 | 189.92 Million EUR | 558.85% |
| 2016 | 28.82 Million EUR | 25.65% |
| 2015 | 22.94 Million EUR | 6.47% |
| 2014 | 21.54 Million EUR | 24.99% |
| 2013 | 17.24 Million EUR | -0.93% |
| 2012 | 17.4 Million EUR | 4.12% |
| 2011 | 16.71 Million EUR | 30.28% |
| 2010 | 12.82 Million EUR | -2.85% |
| 2009 | 13.2 Million EUR | 16.57% |
| 2008 | 11.32 Million EUR | -2.86% |
| 2007 | 11.66 Million EUR | -2.06% |
| 2006 | 11.9 Million EUR | -10.3% |
| 2005 | 13.27 Million EUR | 405.7% |
| 2004 | 2.62 Million EUR | 46.2% |
| 2003 | 1.79 Million EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 473.51 Million EUR | -24.55% |
| 2024 Q1 | 627.55 Million EUR | 0.22% |
| 2023 FY | 626.19 Million EUR | 23.59% |
| 2023 Q2 | 534.14 Million EUR | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | 588.74 Million EUR | 10.22% |
| 2023 Q4 | 626.19 Million EUR | 6.36% |
| 2022 Q4 | 506.67 Million USD | 2.96% |
| 2022 Q3 | 492.09 Million EUR | 1.86% |
| 2022 Q2 | 483.12 Million EUR | -6.83% |
| 2022 Q1 | 518.56 Million EUR | 1.1% |
| 2022 FY | 506.67 Million EUR | -1.22% |
| 2021 Q4 | 512.91 Million EUR | 2.46% |
| 2021 FY | 512.91 Million EUR | 4.26% |
| 2021 Q2 | 512.85 Million EUR | -0.82% |
| 2021 Q1 | 517.07 Million EUR | 5.1% |
| 2021 Q3 | 500.61 Million EUR | -2.39% |
| 2020 Q2 | 489.87 Million EUR | 6.63% |
| 2020 Q1 | 459.4 Million EUR | -0.8% |
| 2020 Q4 | 491.96 Million EUR | 8.21% |
| 2020 Q3 | 454.66 Million EUR | -7.19% |
| 2020 FY | 491.96 Million EUR | 6.23% |
| 2019 FY | 463.09 Million EUR | 304.58% |
| 2019 Q4 | 463.09 Million EUR | 5.6% |
| 2019 Q3 | 438.53 Million EUR | 0.07% |
| 2019 Q1 | 227.2 Million EUR | 98.5% |
| 2019 Q2 | 438.21 Million EUR | 92.87% |
| 2018 Q4 | 114.46 Million EUR | -23.53% |
| 2018 Q2 | 156.46 Million EUR | -14.41% |
| 2018 FY | 114.46 Million EUR | -39.73% |
| 2018 Q1 | 182.8 Million EUR | -3.75% |
| 2018 Q3 | 149.68 Million EUR | -4.33% |
| 2017 Q2 | 7.93 Million EUR | -4.74% |
| 2017 Q1 | 8.32 Million EUR | -71.12% |
| 2017 FY | 189.92 Million EUR | 558.85% |
| 2017 Q4 | 189.92 Million EUR | 10.6% |
| 2017 Q3 | 171.72 Million EUR | 2065.29% |
| 2016 Q1 | 22.62 Million EUR | -1.39% |
| 2016 FY | 28.82 Million EUR | 25.65% |
| 2016 Q4 | 28.82 Million EUR | 94.76% |
| 2016 Q3 | 14.8 Million EUR | -18.66% |
| 2016 Q2 | 18.19 Million EUR | -19.56% |
| 2015 Q1 | 22.23 Million EUR | 3.16% |
| 2015 FY | 22.94 Million EUR | 6.47% |
| 2015 Q3 | 22.93 Million EUR | 1.64% |
| 2015 Q4 | 22.94 Million EUR | 0.05% |
| 2015 Q2 | 22.56 Million EUR | 1.49% |
| 2014 Q1 | 18.17 Million EUR | 5.41% |
| 2014 FY | 21.54 Million EUR | 24.99% |
| 2014 Q4 | 21.54 Million EUR | 0.6% |
| 2014 Q3 | 21.42 Million EUR | 3.84% |
| 2014 Q2 | 20.62 Million EUR | 13.5% |
| 2013 Q1 | 17.37 Million EUR | -0.14% |
| 2013 Q4 | 17.24 Million EUR | -0.26% |
| 2013 FY | 17.24 Million EUR | -0.93% |
| 2013 Q3 | 17.28 Million EUR | -0.26% |
| 2013 Q2 | 17.33 Million EUR | -0.26% |
| 2012 Q4 | 17.4 Million EUR | -2.51% |
| 2012 Q1 | 18.91 Million EUR | 13.15% |
| 2012 Q2 | 19.66 Million EUR | 3.98% |
| 2012 Q3 | 17.85 Million EUR | -9.22% |
| 2012 FY | 17.4 Million EUR | 4.12% |
| 2011 Q3 | 12.09 Million EUR | -8.21% |
| 2011 Q4 | 16.71 Million EUR | 38.23% |
| 2011 Q1 | 13.27 Million EUR | 3.44% |
| 2011 Q2 | 13.17 Million EUR | -0.73% |
| 2011 FY | 16.71 Million EUR | 30.28% |
| 2010 Q4 | 12.82 Million EUR | -13.82% |
| 2010 FY | 12.82 Million EUR | -2.85% |
| 2010 Q3 | 14.88 Million EUR | 16.68% |
| 2010 Q2 | 12.75 Million EUR | -1.85% |
| 2010 Q1 | 13 Million EUR | -1.55% |
| 2009 Q4 | 13.2 Million EUR | 39.22% |
| 2009 Q1 | 10.51 Million EUR | -7.2% |
| 2009 Q2 | 8.99 Million EUR | -14.47% |
| 2009 Q3 | 9.48 Million EUR | 5.49% |
| 2009 FY | 13.2 Million EUR | 16.57% |
| 2008 Q2 | 12.55 Million EUR | 9.43% |
| 2008 Q4 | 11.32 Million EUR | -3.8% |
| 2008 Q3 | 11.77 Million EUR | -6.19% |
| 2008 FY | 11.32 Million EUR | -2.86% |
| 2008 Q1 | 11.47 Million USD | -6.2% |
| 2007 FY | 11.66 Million EUR | -2.06% |
| 2007 Q3 | 7.11 Million EUR | 0.0% |
| 2007 Q4 | 12.22 Million EUR | 71.94% |
| 2006 Q3 | 4.47 Million EUR | 5.62% |
| 2006 Q2 | 4.23 Million EUR | 18.53% |
| 2006 Q4 | 13.02 Million EUR | 191.34% |
| 2006 FY | 11.9 Million EUR | -10.3% |
| 2006 Q1 | 3.57 Million EUR | -4.71% |
| 2005 FY | 13.27 Million EUR | 405.7% |
| 2005 Q2 | 3.08 Million EUR | -3.05% |
| 2005 Q1 | 3.18 Million EUR | 21.36% |
| 2005 Q4 | 3.74 Million EUR | 0.0% |
| 2004 Q1 | 2.52 Million EUR | 40.6% |
| 2004 FY | 2.62 Million EUR | 46.2% |
| 2004 Q4 | 2.62 Million EUR | 0.0% |
| 2004 Q2 | 2.61 Million EUR | 3.74% |
| 2003 FY | 1.79 Million EUR | 0.0% |
| 2003 Q4 | 1.79 Million EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | -961.929% |
| Harrow Health, Inc. | 190.5 Million USD | -228.709% |
| Dynavax Technologies Corporation | 256.91 Million USD | -143.738% |
| Biofrontera Inc. | 5.39 Million USD | -11498.407% |
| Cronos Group Inc. | 2.53 Million USD | -24554.066% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -102893.092% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 12.486% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1623.971% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -53284.041% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -3297.99% |
| Radius Health, Inc. | 365.31 Million USD | -71.414% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -11321.852% |
| DURECT Corporation | 20.74 Million USD | -2918.404% |
| ProPhase Labs, Inc. | 21.38 Million USD | -2828.896% |
| Safety Shot Inc | 1.54 Million USD | -40326.631% |
| Phibro Animal Health Corporation | 525.45 Million USD | -19.172% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -23552.829% |
| Alvotech | 1.07 Billion USD | 41.775% |
| Assertio Holdings, Inc. | 40.91 Million USD | -1430.597% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1407.93% |
| Rockwell Medical, Inc. | 13.43 Million USD | -4559.558% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -95109.554% |
| Procaps Group S.A. | 285.93 Million USD | -119.0% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -3597.001% |
| SCYNEXIS, Inc. | 15.08 Million USD | -4052.507% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -4039.057% |
| Viatris Inc. | 18.12 Billion USD | 96.545% |
| OptiNose, Inc. | 131.74 Million USD | -375.296% |
| SIGA Technologies, Inc. | 1.46 Million USD | -42672.824% |
| Tilray Brands, Inc. | 387.31 Million USD | -61.676% |
| PetIQ, Inc. | 468.3 Million USD | -33.717% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -95109.554% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -46.171% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | -829.091% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 7.131% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -57471.155% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -424.669% |
| Journey Medical Corporation | 17.73 Million USD | -3431.856% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -7465.893% |
| Alpha Teknova, Inc. | 30.45 Million USD | -1955.939% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -29904.696% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -380.361% |
| PainReform Ltd. | 86 Thousand USD | -728037.209% |
| Cosmos Health Inc. | 12.42 Million USD | -4940.248% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -1669.721% |
| TherapeuticsMD, Inc. | 8 Million USD | -7722.586% |
| Embecta Corp. | 1.63 Billion USD | 61.782% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -1046931.284% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | -6.852% |
| Incannex Healthcare Limited | 373 Thousand USD | -167781.501% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -60512.613% |
| Shineco, Inc. | 29.65 Million USD | -2011.507% |
| Procaps Group, S.A. | 285.93 Million USD | -119.0% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -98.586% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -533.663% |
| Lantheus Holdings, Inc. | 616.94 Million USD | -1.5% |
| Alvotech | 1.07 Billion USD | 41.775% |
| Hempacco Co., Inc. | 13.72 Million USD | -4462.627% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -902.462% |
| Bright Green Corporation | 1.85 Million USD | -33715.949% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -15.76% |
| Kamada Ltd. | 8.74 Million USD | -7057.377% |
| Indivior PLC | 281.6 Million USD | -122.37% |
| Evoke Pharma, Inc. | 5 Million USD | -12423.96% |
| Flora Growth Corp. | 3.67 Million USD | -16953.322% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -60512.613% |
| Evolus, Inc. | 126.54 Million USD | -394.838% |
| HUTCHMED (China) Limited | 86.13 Million USD | -627.03% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | -0.41% |
| Akanda Corp. | 3.99 Million USD | -15559.683% |